The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Clinical Trials, Phase II

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Clinical Trials, Phase II


Psychiatry related information on Clinical Trials, Phase II


High impact information on Clinical Trials, Phase II


Chemical compound and disease context of Clinical Trials, Phase II


Biological context of Clinical Trials, Phase II


Anatomical context of Clinical Trials, Phase II


Associations of Clinical Trials, Phase II with chemical compounds


Gene context of Clinical Trials, Phase II


Analytical, diagnostic and therapeutic context of Clinical Trials, Phase II


  1. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. Seidman, A.D., Reichman, B.S., Crown, J.P., Yao, T.J., Currie, V., Hakes, T.B., Hudis, C.A., Gilewski, T.A., Baselga, J., Forsythe, P. J. Clin. Oncol. (1995) [Pubmed]
  2. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Bubley, G.J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W.D., Freidlin, B., Halabi, S., Hudes, G., Hussain, M., Kaplan, R., Myers, C., Oh, W., Petrylak, D.P., Reed, E., Roth, B., Sartor, O., Scher, H., Simons, J., Sinibaldi, V., Small, E.J., Smith, M.R., Trump, D.L., Wilding, G. J. Clin. Oncol. (1999) [Pubmed]
  3. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Stamatoyannopoulos, J.A., Nienhuis, A.W. Annu. Rev. Med. (1992) [Pubmed]
  4. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Gish, R.G. Semin. Liver Dis. (2005) [Pubmed]
  5. The induction of spermidine/spermine N1-acetyltransferase (SSAT) is a common event in the response of human primary non-small cell lung carcinomas to exposure to the new antitumor polyamine analogue N1,N11-bis(ethyl)norspermine. Gabrielson, E.W., Pegg, A.E., Casero, R.A. Clin. Cancer Res. (1999) [Pubmed]
  6. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Mielke, R., Möller, H.J., Erkinjuntti, T., Rosenkranz, B., Rother, M., Kittner, B. Alzheimer disease and associated disorders. (1998) [Pubmed]
  7. Determination of xanomeline in human plasma by ion-spray tandem mass spectrometry. Murphy, A.T., Bonate, P.L., Kasper, S.C., Gillespie, T.A., DeLong, A.F. Biol. Mass Spectrom. (1994) [Pubmed]
  8. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., Mantovani, R. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  9. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Hayden, F.G., Coats, T., Kim, K., Hassman, H.A., Blatter, M.M., Zhang, B., Liu, S. Antivir. Ther. (Lond.) (2002) [Pubmed]
  10. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Thiesing, J.T., Ohno-Jones, S., Kolibaba, K.S., Druker, B.J. Blood (2000) [Pubmed]
  11. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. LaVallee, T.M., Zhan, X.H., Johnson, M.S., Herbstritt, C.J., Swartz, G., Williams, M.S., Hembrough, W.A., Green, S.J., Pribluda, V.S. Cancer Res. (2003) [Pubmed]
  12. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cutts, S.M., Rephaeli, A., Nudelman, A., Hmelnitsky, I., Phillips, D.R. Cancer Res. (2001) [Pubmed]
  13. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Zhang, C., Richon, V., Ni, X., Talpur, R., Duvic, M. J. Invest. Dermatol. (2005) [Pubmed]
  14. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Van Wart, S., Phillips, L., Ludwig, E.A., Russo, R., Gajjar, D.A., Bello, A., Ambrose, P.G., Costanzo, C., Grasela, T.H., Echols, R., Grasela, D.M. Antimicrob. Agents Chemother. (2004) [Pubmed]
  15. The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine against different herpes viruses. Neyts, J., De Clercq, E. Transplantation (1999) [Pubmed]
  16. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. Morse, G.D., Fischl, M.A., Shelton, M.J., Borin, M.T., Driver, M.R., DeRemer, M., Lee, K., Wajszczuk, C.P. Antimicrob. Agents Chemother. (1996) [Pubmed]
  17. The anti-inflammatory effects of a selectin ligand mimetic, TBC-1269, are not a result of competitive inhibition of leukocyte rolling in vivo. Hicks, A.E., Abbitt, K.B., Dodd, P., Ridger, V.C., Hellewell, P.G., Norman, K.E. J. Leukoc. Biol. (2005) [Pubmed]
  18. Histone deacetylase inhibitors--a new tool to treat cancer. Somech, R., Izraeli, S., J Simon, A. Cancer Treat. Rev. (2004) [Pubmed]
  19. Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells. Waselenko, J.K., Shinn, C.A., Willis, C.R., Flinn, I.W., Grever, M.R., Byrd, J.C. Leuk. Lymphoma (2001) [Pubmed]
  20. Pharmacodynamics and tolerability of acetyl starch as a new plasma volume expander in patients undergoing elective surgery. Bremerich, D.H., Lischke, V., Asskali, F., Förster, H., Behne, M. International journal of clinical pharmacology and therapeutics. (2000) [Pubmed]
  21. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. Stangier, J., Su, C.A., Roth, W. J. Int. Med. Res. (2000) [Pubmed]
  22. PBT-1 Prana Biotechnology. Huckle, R. Current opinion in investigational drugs (London, England : 2000) (2005) [Pubmed]
  23. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma. Kuzmits, R., Kokoschka, E.M., Micksche, M., Ludwig, H., Flener, R. Oncology (1985) [Pubmed]
  24. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Tschmelitsch, J., Barendswaard, E., Williams, C., Yao, T.J., Cohen, A.M., Old, L.J., Welt, S. Cancer Res. (1997) [Pubmed]
  25. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures. Wilson, W.R., Giesbrecht, J.L., Hill, R.P., Whitmore, G.F. Cancer Res. (1981) [Pubmed]
  26. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Shih, C., Chen, V.J., Gossett, L.S., Gates, S.B., MacKellar, W.C., Habeck, L.L., Shackelford, K.A., Mendelsohn, L.G., Soose, D.J., Patel, V.F., Andis, S.L., Bewley, J.R., Rayl, E.A., Moroson, B.A., Beardsley, G.P., Kohler, W., Ratnam, M., Schultz, R.M. Cancer Res. (1997) [Pubmed]
  27. Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture. Williams, M.G., Earhart, R.H., Bailey, H., McGovren, J.P. Cancer Res. (1990) [Pubmed]
  28. Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Finney, R.E., Nudelman, E., White, T., Bursten, S., Klein, P., Leer, L.L., Wang, N., Waggoner, D., Singer, J.W., Lewis, R.A. Cancer Res. (2000) [Pubmed]
  29. Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience. de Jonge, E., van der Poll, T., Kesecioglu, J., Levi, M. Semin. Thromb. Hemost. (2001) [Pubmed]
  30. 8-Azapurines as new inhibitors of cyclin-dependent kinases. Havlicek, L., Fuksova, K., Krystof, V., Orsag, M., Vojtesek, B., Strnad, M. Bioorg. Med. Chem. (2005) [Pubmed]
  31. Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors. Piper, P.W., Panaretou, B., Millson, S.H., Trumana, A., Mollapour, M., Pearl, L.H., Prodromou, C. Gene (2003) [Pubmed]
  32. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. Ghosh, A.K., Smith, N.K., Prendiville, J., Thatcher, N., Crowther, D., Stern, P.L. Eur. Cytokine Netw. (1993) [Pubmed]
  33. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Kufe, D., Weichselbaum, R. Cancer Biol. Ther. (2003) [Pubmed]
  34. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Hesketh, P.J., Van Belle, S., Aapro, M., Tattersall, F.D., Naylor, R.J., Hargreaves, R., Carides, A.D., Evans, J.K., Horgan, K.J. Eur. J. Cancer (2003) [Pubmed]
  35. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Giugliano, R.P., Sabatine, M.S., Gibson, C.M., Roe, M.T., Harrington, R.A., Murphy, S.A., Morrow, D.A., Antman, E.M., Braunwald, E. Am. J. Cardiol. (2004) [Pubmed]
  36. Multifaceted roles of cyclooxygenase-2 in lung cancer. Riedl, K., Krysan, K., Põld, M., Dalwadi, H., Heuze-Vourc'h, N., Dohadwala, M., Liu, M., Cui, X., Figlin, R., Mao, J.T., Strieter, R., Sharma, S., Dubinett, S.M. Drug Resist. Updat. (2004) [Pubmed]
  37. New drugs in the treatment of colorectal carcinoma. Punt, C.J. Cancer (1998) [Pubmed]
  38. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Mulato, A.S., Cherrington, J.M. Antiviral Res. (1997) [Pubmed]
WikiGenes - Universities